CMND Clearmind Medicine Inc.
Price Chart
Executive Summary
Clearmind Medicine announced the publication of a Japanese patent application for its MEAI-based depression treatment, expanding its global IP portfolio. This is a routine IP development for a clinical-stage biotech with no revenue, and the filing does not contain financial data or near-term catalysts.
Actionable Insight
This patent filing is a minor positive for IP positioning but does not change the company's near-term outlook. Monitor for clinical trial updates or financing events, as the company has a $2M market cap and likely needs capital.
Key Facts
- Japanese patent application published for MEAI compositions to treat depression.
- MEAI is Clearmind's flagship non-hallucinogenic molecule.
- Company's IP portfolio includes 19 patent families and 31 granted patents.
- No financial data, clinical trial results, or guidance provided in the filing.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company.
Risk Factors
- Patent issuance is not guaranteed and may not be commercially advantageous.
- No revenue or near-term catalysts; high cash burn risk for a $2M market cap company.
- Historical stock volatility is extreme (e.g., -56% T+5 on prior neutral filings).
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-062449 |
| Document: ea029271701ex99-1.htm | 0001213900-26-062449 |
| Document: 0001213900-26-062449-index-headers.html | 0001213900-26-062449 |
| Document: 0001213900-26-062449-index.html | 0001213900-26-062449 |
| Document: 0001213900-26-062449.txt | 0001213900-26-062449 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
3
| $3.36 awaiting T+5 | awaiting T+5 | — | $3.34 (−0.60%) |
|
Jun 5, 2026
8d ago
|
Press Release
| $2.76 awaiting T+5 | awaiting T+5 | — | $3.34 (+21.01%) |
|
May 29, 2026
15d ago
|
6-K
| $3.58 $2.91 | ▼ −18.72% | ▼ −18.42% | $3.34 (−6.70%) |
|
May 29, 2026
15d ago
|
Press Release
| $3.58 $2.91 | ▼ −18.72% | ▼ −18.42% | $3.34 (−6.70%) |
|
May 26, 2026
18d ago
|
6-K
| $2.59 $3.17 | ▲ +22.39% | ▲ +21.31% | $3.34 (+28.96%) |
|
May 26, 2026
18d ago
|
Press Release
| $2.59 $3.17 | ▲ +22.39% | ▲ +21.31% | $3.34 (+28.96%) |
|
May 19, 2026
25d ago
|
6-K
| $2.36 $2.58 | ▼ −9.28% | ▼ −7.04% | $3.34 (−41.53%) |
|
May 19, 2026
25d ago
|
6-K
| $2.36 $2.58 | ▲ +9.28% | ▲ +7.04% | $3.34 (+41.53%) |
|
May 19, 2026
25d ago
|
Press Release
| $2.36 $2.58 | ▼ −9.28% | ▼ −7.04% | $3.34 (−41.53%) |
|
May 18, 2026
25d ago
|
6-K
| $2.36 $2.58 | ▼ −9.28% | ▼ −7.04% | $3.34 (−41.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access